Canagliflozin in Asian patients with type 2 diabetes on metformin alone or metformin in combination with sulphonylurea

At week 18, canagliflozin 100 and 300 mg resulted in reductions in HbA1c levels of -0.97% and -1.06%, respectively, compared to placebo.

• Canagliflozin significantly decreased fasting plasma glucose levels by -1.0 mmol/l with the 100 mg dose and -1.4 mmol/l with the 300 mg dose compared to placebo.
• Both doses of canagliflozin led to reductions in body weight of -2.2% (−1.5 kg) and -2.3% (−1.6 kg) respectively.
• Systolic blood pressure was lowered with both canagliflozin doses compared to placebo.
• The overall incidence of adverse events was 38.6%, 43.2%, and 42.0% for the 100 mg, 300 mg, and placebo groups, respectively.
• The occurrence of genital mycotic infections and urinary tract infections was low and similar across treatment groups.

AI simplified